Drug intelligence / Profile preview

brodifacoum

Development stage
Unknown
Lead developer
Syngenta
Modality
Small Molecules
Administration
Oral (as Bait Formulations)
01

Overview

Brodifacoum is a highly potent second-generation anticoagulant rodenticide of the 4-hydroxycoumarin class. It acts as a vitamin K antagonist by inhibiting the enzyme vitamin K epoxide reductase, thereby blocking the synthesis of vitamin K–dependent clotting factors (II, VII, IX, and X), leading to uncontrolled bleeding in target organisms. Brodifacoum is characterized by its extremely high toxicity to mammals and birds and an exceptionally long biological half-life (up to nine months in humans), which increases risks of secondary poisoning and environmental persistence. It is used primarily for rodent control but has also been employed against larger pests such as possums[2][6]. Human exposure can result in severe coagulopathy requiring prolonged treatment with vitamin K[2].

Brand names
TalonHavoc
Other names
布地格福bromfenacoum3-(3-(4'-bromo-[1,1'-biphenyl]-4-yl)-1,2,3,4-tetrahydronaphthalen-1-yl)-2-hydroxy-4H-chromen-4-one
02

Targets

VKORC1 (Vitamin K epoxide reductase complex subunit 1)

Beyond the preview

Go deeper on brodifacoum.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on brodifacoum.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call